Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XiangLian is a traditional Chinese medicine (TCM) formula, commonly known as Xianglian pill or Xianglian Wan, primarily composed of the herbs Coptidis Rhizoma (Huanglian) and Aucklandiae Radix (Muxiang). It has been historically used to "eliminate damp-heat, promote the flow of qi and relieve pain" for conditions like dysentery, abdominal pain, and diarrhea. Modern research indicates its therapeutic potential in various conditions, including recurrent vulvovaginal candidiasis, tinea pedis, antibiotic-associated diarrhea, ulcerative colitis, pancreatic cancer, dyslipidemia, and colorectal cancer. Its mechanisms of action are diverse, involving the regulation of inflammation, apoptosis, metastasis, and metabolism, inhibition of PTGS1/PTGS2, promotion of autophagy via the PI3K/Akt/mTOR pathway, modulation of gut microbiota and succinate production, induction of regulatory T cells, and inhibition of M1 macrophage polarization. Key active components include berberine, which has been shown to inhibit fatty acid synthase.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on XiangLian.